You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Skip to content

Be alert for signs of renal or pulmonary dysfunctionBe prepared to act on VOD

Signs and symptoms of multi-organ dysfunction may be predictive of VOD progression and poor survival1,2

Stopwatch icon

Early onset1-3

Signs and symptoms such as weight gain, hepatomegaly, and elevated bilirubin may appear early and worsen quickly post HSCT

Exclamation point icon

Rapid worsening2

Short time from the first clinical symptoms to the date of VOD diagnosis

Liver icon

High magnitude of severity1,2,4

Symptoms of severe liver dysfunction and extreme elevation in liver lab values

Approximately 30% to 50% of cases developed multi-organ dysfunction5,a

Liver icon

Renal dysfunction may include3,6-8

  • Decreased urinary output
  • Elevated creatinine levels (≥1.5 x baseline)
  • Decreased creatinine clearance
  • Decreased glomerular filtration rate
  • Need for dialysis
Lungs icon

Pulmonary dysfunction may include1,7,8

  • Pulmonary infiltrates
  • Pleural effusion
  • Reduced oxygen saturation
  • Need for supplemental oxygen (nasal cannula)
  • Ventilator dependence

84% overall mortality in VOD with multi-organ dysfunction9,b

  1. Based on a study conducted by Carreras et al that used 2 sets of diagnostic criteria to estimate the incidence of VOD after HSCT.
  2. Based on 19 studies from a meta-analysis of 135 studies.

VOD can rapidly progress to renal or pulmonary dysfunction1,2,10

Average time of onset of symptoms in VOD post HSCT1,2

Chart Onset

Study design: Time of onset of VOD and multi-organ failure is based on 190 patients from a prospective cohort evaluation of 355 consecutive patients. A diagnosis of VOD was made based on the occurrence of 2 of the following events within 20 days of transplantation: bilirubin >2 mg/dL, hepatomegaly or right upper quadrant pain of hepatic origin, and sudden weight gain (>2% of baseline weight). No other explanation for these signs and symptoms could be present at the time of diagnosis.1,2

HSCT=hematopoietic stem-cell transplantation; VOD=veno-occlusive disease (also known as sinusoidal obstruction syndrome, or SOS).

References: 1. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255-267. 2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005-3020. 3. Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906-912. 4. Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018;53(2):138-145. 5. Carreras E, Díaz-Beyá M, Rosiñol L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011;17(11):1713-1720. 6. Ng CK, Chan MH, Tai MH, et al. Hepatorenal syndrome. Clin Biochem Rev. 2007;28(1):11-17. 7. Richardson PG, Murakami C, Jin Z, et al. Blood. 2002;100(13):4337-4343. 8. Richardson PG, Riches ML, Kernan NA, et al. Blood. 2016;127(13):1656-1665. 9. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-168. 10. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168(4):481-491.